




ONCOSHOT

APAC's Leading Health Insights Exchange & Clinical Trials Platform



Oncoshot is an exceptional solution-oriented company that applies artificial intelligence and federated data sharing models to improve access to clinical trials and accelerate drug development. The platform serves as a trusted and neutral partner providing a safe and secure real-time health data sharing between healthcare systems and industry partners.

Overview

- Oncoshot helps patients, caregivers and oncologists find cancer clinical trials anywhere in the world.
- Founded and based in Singapore, Oncoshot is run by a clinical oncologist from the National Cancer Centre in Singapore and has already expanded into Australia, India, Taiwan and Japan to gather data on all patients nationwide.
- Cancer is the second leading cause of mortality worldwide, and the number of people living with cancer will continue to increase. Thus, the importance for innovative cancer care is rising.
- In the rapidly evolving landscape of cancer care, Oncoshot aims to address the challenge of clinical trials accessibility.
- Its technology allows healthcare systems to share their data with trial institutes and sponsors and receive an immediate response, shortening the clinical trial search from weeks to minutes.
- Niche area of cancer trial provides a \$700 billion total addressable market.
- Market exposure – Australia, India, Taiwan and Singapore.

Technology & Business Model

- The Oncoshot platform deploys low-cost federated databases and generates relevant hospital approved insights for Biopharma in minutes, sorting through over 100,000 deidentified patient profiles.
- Traditionally, this process would take weeks to months. Whereas with Oncoshot, the access to high value clinical trials for cancer patients is immediate.
- The Oncoshot platform serves as a bridge between leading regional healthcare institutions, contract research organizations (CROs), global biotechnology and pharmaceutical companies to facilitate data-driven cancer clinical trials while accelerating enrolment into actively recruiting ones.
- Oncoshot also provides cancer patients, caregivers and their oncologists with personalized and eligible recommendations of clinical trials and curated news.

Key Takeaway

Exceptional Cancer Data Partners

- Upcoming partnerships in major clinical trials markets of Japan, UK and U.S. with continued expansion of data partnerships in Singapore, India, Australia and Taiwan.

Commercialising Big Pharma

- Early success with commercialising big pharma relationships – onboarding strategic large pharma at annual subscription of USD USD 100-120k. Overall pipeline of 10 early engagements and 40+ organisation to be pursued within the ecosystem.

Team

Dr Huren Sivaraj

CEO. Dr Sivaraj is a board-accredited medical oncologist. In addressing challenges at the intersection of informatics and clinical practice, he identified the opportunity and founded Oncoshot.

Srini Srinivasan

Advisor. Dr Srinivasan is passionate about the combined power of science, medicine and tech in improving health. He brings with him over 30 years of experience in global leadership roles at Pfizer, Novartis, GSK and AstraZeneca.

Ruslan Enikeev

CTO. Over 15 years of experience in engineering and data science. He conducted robotics research for the State Scientific Center for Robotics and Technical Cybernetics, and is the creator of the "Map of the Internet."

John McKendry

Advisor. Mr McKendry has over 20 years of commercial experience across Asia within the Pharmaceutical sector. Currently, John is the CEO of Ekomed Technologies and sits as an advisor to various healthcare platforms.

Fundraising

- Oncoshot has raised USD 6 mio to date with the initial seed round in November 2020.
- In June 2022, Oncoshot raised USD 4.5 mio pre-Series A.
- Oncoshot is raising for a \$15 mio Series A.
- Key investors include U.S. insurance giants Mass Mutual, Enterprise SG, Lion City Capital and 5 C-Suite level executives.

Key Activities over the next 12 months

- Market consolidation within Singapore: Onboarding large/global cancer pharma and CROs and deployment of Oncoshot for MOH supported clinical trials under SCRI.
- Market expansion within India, Australia, Taiwan, Japan, U.S. and China.
- Launch of new products for Pharma commercial and market access units to leverage existing data infrastructure.

Impact

- Oncoshot strives towards having a positive impact on low-income and rural populations.
- Thus far, Oncoshot has been highly successful in sharing the benefits of productive cancer trials and therapies with poorer and marginalized sections of society.



About Milltrust International

With its mantra of “Sustainable Prosperity”, Milltrust International Group is a global investment organisation making sustainable impact investments in the biggest themes of our generation: climate change, the demand for food and protein, the future of medical technology, and the rise of the developing world.

Over the past decade, Milltrust has assembled a highly experienced team of leading industry professionals focused exclusively on providing investment management expertise on both public and private markets.

Milltrust’s private investments consist of a plethora of science-backed early-stage disruptive companies in the space of climate impact, healthcare, and agriculture. By drawing on the experience of investment bankers, asset managers, healthcare professionals, and agronomists, our diversified assets have pioneered breakthrough technology in environmental management, medical diagnostics, and animal genetics and welfare with the aim of delivering sustainable solutions an ever-growing and increasingly ageing global population.

About The British Innovation Fund II

The British Innovation Fund II follows on from the success of The British Innovation Fund I, investing into high potential companies with a focus on agri-tech, the future of healthcare, climate impact, and alternative protein, where incontrovertible science is at the core of the commercial proposition.

More Information

Milltrust International UK

6 Stratton Street
London W1J 8LD
United Kingdom

+44 (0)20 8123 8316

info@milltrust.com

Milltrust International Singapore

77B Tras Steet
Singapore 079016
Singapore

+65 6225 3052

info@milltrust.com

Signatory of:



Disclaimer

For professional investors only. This document is strictly private and confidential and is meant as guidance and information only. It is issued by Milltrust International LLP which is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. Milltrust Ventures Pte Ltd is a subsidiary of Milltrust International Group (Singapore) Pte. Ltd and is registered with the Monetary Authority of Singapore as a Venture Capital Fund Management Company (VCFM). The content in this document is for informational purposes only and does not constitute legal, tax, investment, financial, or other advice. Nothing contained in this document constitutes a solicitation, recommendation, endorsement, or offer by Milltrust International LLP or any of its affiliates to buy or sell any securities or other financial instruments. No such solicitation or offer is made in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this document is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the document constitutes professional and/or financial advice, nor does any information on the document constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. It should therefore not be used as the sole basis for any investment or other decision. The use of or access to this document or content by any person does not create a fiduciary relationship between such person and Milltrust International LLP. The sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this document before making any decisions based on such information or other content rests with the user and their professional advisers. Notice to US investors: The shares of Milltrust International Managed Investments ICAV have not been registered under the 1933 Securities Act or under the 1940 Act; however, the company takes advantage of the 3(c)7 exemption and shares are available to 3(C)(1) US “qualified purchasers” and those qualifying under Reg D. Distribution activity in the US is undertaken by Silverleaf Partners LLC, a registered broker-dealer based in New York. Beyond providing initial capital for the companies we invest in, Milltrust may also leverage its extensive network to support our portfolio companies on a commercial basis with additional capital raises as they grow. Whether through introductions to potential investors, strategic partnerships, or other value-add services, we are committed to helping our portfolio companies succeed. Milltrust may receive compensation for services rendered to this company.